Vimarsana
Biggest News Aggregation in the World

Page 48 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene announces Novartis collaboration on antibody - Vimarsana News

BeiGene announces Novartis collaboration on antibody

BeiGene announces Novartis collaboration on antibody By Liu Zhihua | chinadaily.com.cn | Updated: 2021-01-13 11:13 Share CLOSE Scientists discuss use of equipment at the central chemistry lab of BeiGene in Beijing in May 2017. [Photo provided to chinadaily.com.cn] China-based biotechnology company BeiGene Ltd held a media conference in Beijing on Tuesday to announce its collaboration and license agreement with Swiss pharmaceutical company Novartis Pharma AG for development and commercialization of the cancer treatment tislelizumab. Th...

BeiGene Collaborates With Novartis To Develop Cancer Drug; To Receive Up To $1.55 Bln Payments - Vimarsana News

BeiGene Collaborates With Novartis To Develop Cancer Drug; To Receive Up To $1.55 Bln Payments

BASEL (dpa-AFX) - China-based biotechnology companyBeiGene Ltd. (BGNE) said that it will collaborate with Novartis to develop, manufacture and commercialize BeiGene's cancer drug tislelizumab

Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy - Vimarsana News

Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy

Message : Required fields (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhan's move, which could bring $1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data quality and innovation worries as barriers to Big Pharma's Chinese M&A dreams. Novartis will co-develop BeiGene's tislelizumab, an anti-PD-1 antibody simil...

RPT-UPDATE 1-Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy - Vimarsana News

RPT-UPDATE 1-Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy

* Novartis’s China foray follows Pfizer deal in September * Swiss drugmaker playing catch-up on cancer immunotherapy * Novartis CEO was previously tepid on Chinese assets Jan 12 (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd , the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhan’s move, which could bring $1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data qua...

Twitter, Tesla, Realty Income, Cantel Medical: What to Watch When the Stock Market Opens Today - Vimarsana News

Twitter, Tesla, Realty Income, Cantel Medical: What to Watch When the Stock Market Opens Today

Here’s what we’re watching as markets kick into gear on Tuesday. — U.S. stock futures edged higher Tuesday, suggesting major indexes will resume their recent climb after a slide in technology shares weighed on markets at the start of the week. Read our full market wrap here. What’s Coming Up —Home builder KB Home will deliver its quarterly earnings report after markets close. —Live Q&A: Join WSJ chief economics correspondent Nick Timiraos for an interview with the St. Louis Fed’s James Bullard. Bullard at 1 p.m. ET. —The U.S. job openings and labor turnover survey for Novemb...

Source: wsj.com